Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| DTCK | Davis Commodities | $2.34 | $0.91 | 63.64% | 18.6M | $39M | $1.32$137.80 |
| ANTX | An2 Therapeutics | $4.30 | $1.45 | 50.70% | 7.8M | $78M | $1.00$4.30 |
| XENE | Xenon Pharmaceuticals | $61.55 | $19.61 | 46.76% | 373.6K | $3.5B | $26.74$62.40 |
| TURB | Turbo Energy | $5.51 | $1.73 | 45.77% | 12.6M | $42M | $0.57$20.45 |
| HIMS | Hims & Hers Health | $21.78 | $6.04 | 38.37% | 3.8M | $3.6B | $13.74$70.43 |
| RLMD | Relmada Therapeutics | $5.99 | $1.54 | 34.61% | 29.1M | $326M | $0.24$6.52 |
| PROP | Prairie Operating, Llc | $2.08 | $0.48 | 29.69% | 5.9M | $95M | $1.50$6.90 |
| PLYX | Polaryx Therapeutics | $3.49 | $0.75 | 27.19% | 245.5K | $130M | $2.20$48.91 |
| DNTH | Dianthus Therapeutics | $82.41 | $17.21 | 26.39% | 2.4M | $2.8B | $13.37$84.86 |
| AGCC | Agencia Comercial Spirits | $22.50 | $4.39 | 24.24% | 1.1K | $623M | $3.66$22.50 |
| ATRA | Atara Biotherapeutics | $6.40 | $1.23 | 23.79% | 33.8K | $37M | $3.92$19.15 |
| QURE | uniQure | $17.35 | $3.08 | 21.58% | 343.9K | $879M | $7.76$71.50 |
| NERV | Minerva Neurosciences | $7.24 | $1.23 | 20.47% | 115K | $260M | $1.15$12.46 |
| RGNX | Regenxbio | $10.40 | $1.75 | 20.23% | 872.3K | $438M | $5.04$16.19 |
| LSTA | Lisata Therapeutics | $5.01 | $0.83 | 19.86% | 252.6K | $37M | $1.81$5.06 |
| EDIT | Editas Medicine | $2.37 | $0.37 | 18.50% | 100.7K | $195M | $0.91$4.54 |
| NCSM | Ncs Multistage | $56.99 | $8.64 | 17.87% | 673 | $123M | $25.09$58.09 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $4.09 | $0.62 | 17.87% | 20.7M | - | $0.95$20.92 |
| BEG | Themes ETF Trust - Leverage Shares 2x Long Be Daily ETF | $30.75 | $4.61 | 17.63% | 26.6K | - | $10.89$50.61 |
| PURR | Hyperliquid Strategies | $5.05 | $0.72 | 16.51% | 2.8M | $537M | $3.01$5.78 |
| WTI | W&T Offshore | $3.64 | $0.50 | 15.92% | 339.8K | $467M | $1.09$4.04 |
| KC | Kingsoft Cloud | $13.85 | $1.86 | 15.51% | 63.8K | $3.5B | $10.29$19.57 |
| SLDB | Solid Biosciences | $7.76 | $1.01 | 14.96% | 46.4K | $526M | $2.41$8.15 |
| VRTL | GraniteShares ETF Trust - GraniteShares 2x Long Vrt Daily ETF | $112.63 | $13.74 | 13.89% | 123.3K | - | $7.57$119.89 |
| TAOX | Tao Synergies | $4.49 | $0.52 | 13.10% | 43.4K | $30M | $1.84$11.98 |
| DYN | Dyne Therapeutics | $16.75 | $1.89 | 12.72% | 718.2K | $2.5B | $6.36$25.00 |
| NBTX | Nanobiotix | $38.23 | $4.24 | 12.47% | 548 | $1.6B | $2.95$38.23 |
| EDSA | Edesa Biotech | $7.29 | $0.77 | 11.76% | 2.1M | $54M | $0.72$7.60 |
| CAMP | Camp4 Therapeutics | $4.67 | $0.47 | 11.19% | 7.6K | $218M | $1.31$7.31 |
Related Articles
Featured Article
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?
Geoffrey Seiler|Feb 27, 2026
The company is looking toward international markets to boost its growth.
Hims & Hers HUGE Acquisition News!
Travis Hoium|Feb 19, 2026
Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
Bram Berkowitz|Feb 9, 2026
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
Selena Maranjian|Nov 24, 2025
It has grown wildly, and it could keep growing.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
